Acadia pharmaceuticals announces exclusive license agreement with saniona for san711

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced it has entered into an exclusive worldwide license agreement with saniona (omx: sanion) for the development and commercialization of san711, a first-in-class, highly selective gabaa-Α3 positive allosteric modulator. the first indication the company plans to pursue is development of san711 for essential tremor, a neurological condition that includes shaking or trembling movements in one or more parts of the bo.
ACAD Ratings Summary
ACAD Quant Ranking